A gene expression signature associated with survival in metastatic melanoma

Susanna Mandruzzato, Andrea Callegaro, Gianluca Turcatel, Samuela Francescato, Maria C. Montesco, Vanna Chiarion-Sileni, Simone Mocellin, Carlo R. Rossi, Silvio Bicciato, Ena Wang, Francesco M. Marincola, Paola Zanovello

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: Current clinical and histopathological criteria used to define the prognosis of melanoma patients are inadequate for accurate prediction of clinical outcome. We investigated whether genome screening by means of high-throughput gene microarray might provide clinically useful information on patient survival. Methods: Forty-three tumor tissues from 38 patients with stage III and stage IV melanoma were profiled with a 17,500 element cDNA microarray. Expression data were analyzed using significance analysis of microarrays (SAM) to identify genes associated with patient survival, and supervised principal components (SPC) to determine survival prediction. Results: SAM analysis revealed a set of 80 probes, corresponding to 70 genes, associated with survival, i.e. 45 probes characterizing longer and 35 shorter survival times, respectively. These transcripts were included in a survival prediction model designed using SPC and cross-validation which allowed identifying 30 predicting probes out of the 80 associated with survival. Conclusion: The longer-survival group of genes included those expressed in immune cells, both innate and acquired, confirming the interplay between immunological mechanisms and the natural history of melanoma. Genes linked to immune cells were totally lacking in the poor-survival group, which was instead associated with a number of genes related to highly proliferative and invasive tumor cells.

Original languageEnglish
Article number50
JournalJournal of Translational Medicine
Volume4
DOIs
Publication statusPublished - 27 Nov 2006
Externally publishedYes

Fingerprint

Transcriptome
Gene expression
Melanoma
Genes
Microarrays
Survival
Tumors
Microarray Analysis
Screening
Oligonucleotide Array Sequence Analysis
Complementary DNA
Cells
Throughput
Tissue
Neoplasms
Genome

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Mandruzzato, S., Callegaro, A., Turcatel, G., Francescato, S., Montesco, M. C., Chiarion-Sileni, V., ... Zanovello, P. (2006). A gene expression signature associated with survival in metastatic melanoma. Journal of Translational Medicine, 4, [50]. https://doi.org/10.1186/1479-5876-4-50

A gene expression signature associated with survival in metastatic melanoma. / Mandruzzato, Susanna; Callegaro, Andrea; Turcatel, Gianluca; Francescato, Samuela; Montesco, Maria C.; Chiarion-Sileni, Vanna; Mocellin, Simone; Rossi, Carlo R.; Bicciato, Silvio; Wang, Ena; Marincola, Francesco M.; Zanovello, Paola.

In: Journal of Translational Medicine, Vol. 4, 50, 27.11.2006.

Research output: Contribution to journalArticle

Mandruzzato, S, Callegaro, A, Turcatel, G, Francescato, S, Montesco, MC, Chiarion-Sileni, V, Mocellin, S, Rossi, CR, Bicciato, S, Wang, E, Marincola, FM & Zanovello, P 2006, 'A gene expression signature associated with survival in metastatic melanoma', Journal of Translational Medicine, vol. 4, 50. https://doi.org/10.1186/1479-5876-4-50
Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V et al. A gene expression signature associated with survival in metastatic melanoma. Journal of Translational Medicine. 2006 Nov 27;4. 50. https://doi.org/10.1186/1479-5876-4-50
Mandruzzato, Susanna ; Callegaro, Andrea ; Turcatel, Gianluca ; Francescato, Samuela ; Montesco, Maria C. ; Chiarion-Sileni, Vanna ; Mocellin, Simone ; Rossi, Carlo R. ; Bicciato, Silvio ; Wang, Ena ; Marincola, Francesco M. ; Zanovello, Paola. / A gene expression signature associated with survival in metastatic melanoma. In: Journal of Translational Medicine. 2006 ; Vol. 4.
@article{1e9cbc84e7bb4956a47886fb06d7d7a9,
title = "A gene expression signature associated with survival in metastatic melanoma",
abstract = "Background: Current clinical and histopathological criteria used to define the prognosis of melanoma patients are inadequate for accurate prediction of clinical outcome. We investigated whether genome screening by means of high-throughput gene microarray might provide clinically useful information on patient survival. Methods: Forty-three tumor tissues from 38 patients with stage III and stage IV melanoma were profiled with a 17,500 element cDNA microarray. Expression data were analyzed using significance analysis of microarrays (SAM) to identify genes associated with patient survival, and supervised principal components (SPC) to determine survival prediction. Results: SAM analysis revealed a set of 80 probes, corresponding to 70 genes, associated with survival, i.e. 45 probes characterizing longer and 35 shorter survival times, respectively. These transcripts were included in a survival prediction model designed using SPC and cross-validation which allowed identifying 30 predicting probes out of the 80 associated with survival. Conclusion: The longer-survival group of genes included those expressed in immune cells, both innate and acquired, confirming the interplay between immunological mechanisms and the natural history of melanoma. Genes linked to immune cells were totally lacking in the poor-survival group, which was instead associated with a number of genes related to highly proliferative and invasive tumor cells.",
author = "Susanna Mandruzzato and Andrea Callegaro and Gianluca Turcatel and Samuela Francescato and Montesco, {Maria C.} and Vanna Chiarion-Sileni and Simone Mocellin and Rossi, {Carlo R.} and Silvio Bicciato and Ena Wang and Marincola, {Francesco M.} and Paola Zanovello",
year = "2006",
month = "11",
day = "27",
doi = "10.1186/1479-5876-4-50",
language = "English",
volume = "4",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - A gene expression signature associated with survival in metastatic melanoma

AU - Mandruzzato, Susanna

AU - Callegaro, Andrea

AU - Turcatel, Gianluca

AU - Francescato, Samuela

AU - Montesco, Maria C.

AU - Chiarion-Sileni, Vanna

AU - Mocellin, Simone

AU - Rossi, Carlo R.

AU - Bicciato, Silvio

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Zanovello, Paola

PY - 2006/11/27

Y1 - 2006/11/27

N2 - Background: Current clinical and histopathological criteria used to define the prognosis of melanoma patients are inadequate for accurate prediction of clinical outcome. We investigated whether genome screening by means of high-throughput gene microarray might provide clinically useful information on patient survival. Methods: Forty-three tumor tissues from 38 patients with stage III and stage IV melanoma were profiled with a 17,500 element cDNA microarray. Expression data were analyzed using significance analysis of microarrays (SAM) to identify genes associated with patient survival, and supervised principal components (SPC) to determine survival prediction. Results: SAM analysis revealed a set of 80 probes, corresponding to 70 genes, associated with survival, i.e. 45 probes characterizing longer and 35 shorter survival times, respectively. These transcripts were included in a survival prediction model designed using SPC and cross-validation which allowed identifying 30 predicting probes out of the 80 associated with survival. Conclusion: The longer-survival group of genes included those expressed in immune cells, both innate and acquired, confirming the interplay between immunological mechanisms and the natural history of melanoma. Genes linked to immune cells were totally lacking in the poor-survival group, which was instead associated with a number of genes related to highly proliferative and invasive tumor cells.

AB - Background: Current clinical and histopathological criteria used to define the prognosis of melanoma patients are inadequate for accurate prediction of clinical outcome. We investigated whether genome screening by means of high-throughput gene microarray might provide clinically useful information on patient survival. Methods: Forty-three tumor tissues from 38 patients with stage III and stage IV melanoma were profiled with a 17,500 element cDNA microarray. Expression data were analyzed using significance analysis of microarrays (SAM) to identify genes associated with patient survival, and supervised principal components (SPC) to determine survival prediction. Results: SAM analysis revealed a set of 80 probes, corresponding to 70 genes, associated with survival, i.e. 45 probes characterizing longer and 35 shorter survival times, respectively. These transcripts were included in a survival prediction model designed using SPC and cross-validation which allowed identifying 30 predicting probes out of the 80 associated with survival. Conclusion: The longer-survival group of genes included those expressed in immune cells, both innate and acquired, confirming the interplay between immunological mechanisms and the natural history of melanoma. Genes linked to immune cells were totally lacking in the poor-survival group, which was instead associated with a number of genes related to highly proliferative and invasive tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=33845783311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845783311&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-4-50

DO - 10.1186/1479-5876-4-50

M3 - Article

VL - 4

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 50

ER -